Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity

@article{Singhal2014PhaseIS,
  title={Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity},
  author={Nimit Singhal and Sina Vatandoust and Michael Paul Brown},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2014},
  volume={75},
  pages={325-331}
}
AbstractIntroduction Lung cancer is one of the most common malignancies worldwide. Non-small cell lung cancer (NSCLC) comprises the majority of the cases of lung cancer. Previous studies have demonstrated a role for both the estrogen pathway and mammalian target of rapamycin (mTOR) in NSCLC.MethodsThis single-arm phase 2 study was designed to assess the safety and efficacy of combination treatment with aromatase inhibitor—letrozole—and mTOR inhibitor—everolimus—in the treatment of patients with… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.

  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2013
VIEW 1 EXCERPT